N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide manufacturers
- CPPHA
-
- $29.00
-
2026-07-04
- CAS:693288-97-0
- Purity: 99.70%
- Supply Ability: 10g
- CPPHA
-
- $29.00
-
2026-07-04
- CAS:693288-97-0
- Purity: 99.70%
- Supply Ability: 10g
|
| | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide Basic information |
| Product Name: | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide | | Synonyms: | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide;N-[4-Chloro-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide;N-[4-Chloro-2-(phthalimidomethyl)phenyl]salicylamide;CPPHA;Benzamide, N-[4-chloro-2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]phenyl]-2-hydroxy-;N-[4-chloro-2-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]-2-hydroxybenzamide;CPPHA, 10 mM in DMSO | | CAS: | 693288-97-0 | | MF: | C22H15ClN2O4 | | MW: | 406.82 | | EINECS: | | | Product Categories: | | | Mol File: | 693288-97-0.mol | ![N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide Structure](CAS/GIF/693288-97-0.gif) |
| | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide Chemical Properties |
| Boiling point | 539.7±50.0 °C(Predicted) | | density | 1.505 | | storage temp. | -20°C | | solubility | DMSO: >20mg/mL | | form | solid | | pka | 8.24±0.30(Predicted) | | color | Light yellow to yellow |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 |
| | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide Usage And Synthesis |
| Description | CPPHA is a positive allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) that potentiates human and rat mGluR5 activation by glutamate, 3,5-DHPG , and quisqualate (EC50s = 0.316-0.5 and 0.634-1.16 μM for human and rat mGluR5, respectively). It is selective for mGluR5 over other mGluRs but exhibits submicromolar activity at PDE6, δ- and κ-opioid receptors, and the ether-a-go-go related gene (ERG) potassium channel (Kis = 500, 352, 474, and 813 nM, respectively). CPPHA potentiates 3,5-DHPG-induced NMDA currents in CA1 pyramidal cells and the depolarization of rat subthalamic nucleus (STN) neurons. | | Uses | CPPHA is potent and selective positive allosteric modulator (PAM) of the mGluR5 and mGluR1 (metabotropic glutamate receptor). CPPHA can potentiate responses of mGluR5 and mGluR1 to activation of these receptors. CPPHA is developed for the research of central nervous system disorders[1][2]. | | IC 50 | mGlu5 Receptor | | References | [1] O'Brien JA, et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther. 2004 May;309(2):568-77. DOI:10.1124/jpet.103.061747
[2] N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol. 2008 Mar;73(3):909-18. DOI:10.1124/mol.107.040097
[3] Liu F, et al. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur J Pharmacol. 2006 May 1;536(3):262-8. DOI:10.1016/j.ejphar.2006.02.003
[4] Zhang Y, et al. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther. 2005 Dec;315(3):1212-9. DOI:10.1124/jpet.105.090308 |
| | N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide Preparation Products And Raw materials |
|